General Information of Drug (ID: DMOOHDN)

Drug Name
CX-904 Drug Info
Synonyms AMG 651
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMOOHDN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [3]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [4]
Gefitinib DM15F0X Colon adenocarcinoma Approved [5]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [6]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [7]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [8]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [9]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [10]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [8]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [12]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [13]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [14]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [15]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [16]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [17]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [18]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [19]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [20]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Not Available [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [2]

References

1 ClinicalTrials.gov (NCT05387265) A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of CytomX
3 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
4 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
5 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
6 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
7 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
9 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
10 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
12 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
13 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
14 Clinical pipeline report, company report or official report of Genmab.
15 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
16 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
17 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
18 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
19 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
20 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
21 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.